

UDK 616.89-053.3-092 + 636.22-053 + 616.348-002 + 615 + 57.084.5  
DOI: 10.56871/CmN-W.2024.42.28.003

## INFANTILE COLIC

© Valeria P. Novikova, Dinara M. Magamedova

Saint Petersburg State Pediatric Medical University, Lithuania 2, Saint Petersburg, Russian Federation, 194100

**Contact information:**

Valeria P. Novikova — Doctor of Medical Sciences, Professor, Head of the Department of Propaedeutics of Children's Diseases with a Course in General Child Care, Head of the Laboratory of Medical and Social Problems in Pediatrics, National Research Center.  
E-mail: novikova-vp@mail.ru ORCID ID: 0000-0002-0992-1709 SPIN: 1875-8137

**For citation:** Novikova VP, Magamedova DM. Infantile colic. Children's Medicine of the North-West (St. Petersburg). 2024;12(1):30-48.  
DOI: <https://doi.org/10.56871/CmN-W.2024.42.28.003>

**Received:** 04.12.2023

**Revised:** 29.12.2023

**Accepted:** 25.01.2024

**Abstract.** The lecture is devoted to the current problem of pediatrics — infant colic. They are in the light of the recommendations of the Rome criteria, reflecting the opinion of experts — pediatricians, gastroenterologists, allergists. The key to diagnosing infant colic is to exclude organic pathology ("red flags"), which accounts for no more than 5%. The article discusses modern ideas about the pathogenetic mechanisms of infant colic and modern principles of their correction based on these data. Correction of infant colic includes psychological support for the family, continued breastfeeding and the use of probiotics.

**Key words:** *infant colic; "red flags"; Rome IV criteria; probiotics.*

## МЛАДЕНЧЕСКИЕ КОЛИКИ

© Валерия Павловна Новикова, Динара Мафрутдиновна Магамедова

Санкт-Петербургский государственный педиатрический медицинский университет. 194100, г. Санкт-Петербург, ул. Литовская, 2

**Контактная информация:**

Валерия Павловна Новикова — д.м.н., профессор, заведующий кафедрой пропедевтики детских болезней с курсом общего ухода за детьми, заведующий лабораторией «Медико-социальных проблем в педиатрии» НИЦ.  
E-mail: novikova-vp@mail.ru ORCID ID: 0000-0002-0992-1709 SPIN: 1875-8137

**Для цитирования:** Новикова В.П., Магамедова Д.М. Младенческие колики // Children's Medicine of the North-West. 2024. Т. 12. № 1. С. 30–48. DOI: <https://doi.org/10.56871/CmN-W.2024.42.28.003>

**Поступила:** 04.12.2023

**Одобрена:** 29.12.2023

**Принята к печати:** 25.01.2024

**Резюме.** Лекция посвящена актуальной проблеме педиатрии — младенческим коликам. Они рассматриваются в свете рекомендаций Римских критериев, отражающих мнение экспертов — педиатров, гастроэнтерологов, аллергологов. Ключевым моментом в постановке диагноза младенческих колик является исключение органической патологии («красные флаги»), которая составляет не более 5%. В статье рассмотрены современные представления о патогенетических механизмах младенческих колик и основанные на этих данных современные принципы их лечения. Терапия младенческих колик включает психологическую поддержку семьи, сохранение грудного вскармливания и применение пробиотиков.

**Ключевые слова:** *младенческие колики; «красные флаги»; Римские критерии IV; пробиотики.*

The term "colic" (colicos) means "pain in the large intestine". Colic is an attack-like pain in the abdomen accompanied by marked restlessness and crying of an infant in the first months of life [1].

A meta-analysis (2017) included 28 diary studies covering 8690 infants, showed that the average daily duration of crying in infants amounts from 117 to 133 minutes per day in the first

6 weeks of life, and to 68 minutes per day — from 10 to 12 weeks of life [2]. The WhyCry 2G crying analyzer identifies five reasons for infant crying: hunger, boredom, pain, sleep and stress. It is estimated that less than 5% of infants have identifiable medical explanations for their crying [3]. Unreasonable infants' cry began to attract the attention of the medical community since the

1890s. For the first time, an infantile colic (IC) was described by M. Wessell et al. in the 1960s [4]. The criteria proposed by M. Wessell et al. were used to diagnose colic for a long time. The criteria consists of the so-called rule of three: crying for 3 hours a day or more (usually not longer than 1 hour), at least 3 days a week, for 3 consecutive weeks; age from 6 weeks to 3–4 months; a good general condition: children have good weight gain, maintain a positive emotional attitude, good appetite, normal stools; possible infrequent regurgitation; absence of "anxiety symptoms". Clinical practice has shown that it was hard for parents to evaluate periods of crying and anxiety retrospectively, thus the Wessell criteria were considered inappropriate for practical use since they were associated with certain difficulties and diagnostic errors. According to the Rome IV criteria revision committee, the Wessell criteria are random, culturally independent, impractical, and do not reflect the impact of the child's symptoms on the family. For this reason, the new clinical criteria are based on symptoms that have been shown to cause more discomfort for parents. In addition, the Rome IV criteria extended the age of IC diagnosis to 5 months [5]. Thus, for clinical purposes, the diagnostic criteria should include following features: an infant under 5 months old at the beginning and end of symptoms; recurrent and prolonged periods of crying, restlessness, or irritability reported by caregivers, occurring for no apparent reason and that cannot be prevented or managed by caring adults; no evidence of developmental delay, fever, or illness with clinical signs, i.e., "red flags" or "anxiety symptoms" [5]. "Anxiety symptoms" indicate organic diseases manifesting itself in fever, persistent regurgitation including coughing fits, absence of weight gain, mucus and blood in stools, passive abdominal wall tension, refusal to eat, abdominal bloating, signs of atopic dermatitis and persistent constipation.

IC is defined as one of the most common complaints that parents address to primary care physicians [6, 7]. A recently published systematic review (2020) reported colic incidence rates ranging from 2 to 73% [8]. Symptoms peak around the sixth week of life and cease naturally after 4–6 months of age [9], allowing it to be considered a benign, self-healing condition.

The need to treat this self-healing condition stems from the negative impact of excessive crying on an infant's family. Prolonged infant crying is harmful to sibling-parent relationships [10], is

associated with maternal problems such as depression, anxiety, and loss of parental confidence [11, 12], is a frequent cause of early cessation of breastfeeding [13], and can lead to severe infant injury or death due to abuse [14]. A second important argument for the treatment of colic is the presence of its long-term consequences, such as migraine, sleep and behavioral disorders, hyperactivity, decreased intelligence and cognitive disorders, eating disorders, atopic diseases and functional gastrointestinal (GI) diseases [15–18]. Knowledge of IC pathogenesis is necessary for selecting an adequate therapy.

Infantile colic has a multifactorial pathogenesis. Physiologic imbalance in the development of the central nervous system explains the time of IC manifestation. At the age of 2 months, brain systems tolerate changes, as a result reflex mechanisms supervising behavioral responses are replaced by a system of control proceeded by the cerebral cortex. Many authors believe that inconsolable crying, which is noted in infantile colics, is a consequence of transient behavioral response deficits in the first 2 months of life [19, 20]. Complex interactions between behavioral factors (psychological and social) such as postpartum depression, parental anxiety, stressful pregnancy, adverse experiences during delivery, poor parenting skills [24–26], alterations from the endogenous opioid system and neuropeptide regulation [27–31], as well as nutritional factors (hypersensitivity or food allergy, especially allergy to cow's milk proteins) [28, 30], immaturity of gastrointestinal tract (GIT) [21, 24, 32], excessive intestinal gases [21, 24], imbalance of intestinal hormones and impaired intestinal motility [31, 32], changes in the intestinal microbiota [33, 34], disruption of the microbiota-brain axis [35], impaired intestinal permeability and low intensity inflammation [22, 36, 37] are among numerous mechanisms that play a role in the pathogenesis of colic.

The role of the gut microbiota has the greatest evidence base in the colic pathogenesis. Table 1 summarizes studies examining the quantitative and qualitative composition of the microbiota in children with and without IC.

Despite the diversity of results, most researchers indicate a low qualitative diversity of intestinal microbiota in children with colic compared to the microbiota of children without colic during the first 2 weeks of life [39]. Other studies suggest the presence of certain microorganisms in the gut microbiota associated with increased

**Table 1. Studies of microbiota composition in children with colic and healthy infants**

**Таблица 1. Исследования состава микробиоты у детей с коликами и здоровых младенцев**

Автор / Author	Метод / Method	Результаты / Results
Savino et al., 2004 [38]	Культуральный / Cultural	Младенцы с коликами имеют более высокие показатели и плотность кишечной палочки и других газообразующих кишечных палочек и более низкие уровни <i>Lactobacillus</i> spp. по сравнению со здоровыми младенцами / Colicky infants have higher counts and densities of <i>E. coli</i> and other gas-forming coliforms and lower levels of <i>Lactobacillus</i> spp. compared to healthy babies
Savino et al., 2009 [39]	Культуральный + ПЦР / Culture + PCR	<i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>K. oxytoca</i> , <i>Enterobacter cloacae</i> , <i>E. aerogenes</i> и <i>Enterococcus faecalis</i> были преобладающими видами у младенцев с коликами / <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>K. oxytoca</i> , <i>Enterobacter cloacae</i> , <i>E. aerogenes</i> and <i>Enterococcus faecalis</i> were the predominant species in colicky infants
Mentula S., 2009 [40]	Культуральный + анализ клеточных жирных кислот, КЦЖК и производства газов / Culture + analysis of cellular fatty acids, SCFAs and gas production	Распространенность индолпродуцирующих колиформ была значительно выше у младенцев с коликами по сравнению с контрольной группой, в то время как многие аэробные роды, присутствующие в контрольной группе, не были обнаружены у младенцев с коликами / The prevalence of indole-producing coliforms was significantly higher in colicky infants compared with controls, while many aerobic labors present in controls were not found in colicky infants
de Weerth C., 2013 [41]	Молекулярные методы / Molecular methods	Colic phenotype was positively correlated with <i>Serratia</i> , <i>Vibrio</i> and <i>Pseudomonas</i> content / Фенотип колик положительно коррелировал с содержанием <i>Serratia</i> , <i>Vibrio</i> и <i>Pseudomonas</i>
Rhoads J.M., 2018 [42]	Секвенирование ДНК / DNA sequencing	Таксоны, которые в значительной степени связаны с коликами: <i>Acinetobacter</i> , <i>Lactobacillus iners</i> . Снижение относительного содержания бифидобактерий в среднем в 30 раз / Taxa significantly associated with colic: <i>Acinetobacter</i> , <i>Lactobacillus iners</i> . Reduction in the relative content of bifidobacteria by an average of 30 times
Loughman A, et al., 2021 [43]	Секвенирование 16S рРНК / 16S rRNA sequencing	Альфа-разнообразие фекальной микробиоты не имело существенной связи с плачом. Несколько таксонов микробиоты (включая <i>Bifidobacterium</i> , <i>Clostridium</i> , <i>Lactobacillus</i> и <i>Klebsiella</i> ) связаны с тяжестью колик / Alpha diversity of fecal microbiota was not significantly associated with crying. Several microbiota taxa (including <i>Bifidobacterium</i> , <i>Clostridium</i> , <i>Lactobacillus</i> , and <i>Klebsiella</i> ) are associated with colic severity
Kozhakhmetov S., 2023 [44]	Полное метагеномное секвенирование образцов кала / Whole metagenomic sequencing of stool samples	В группе колик обнаружено относительное изобилие <i>Bifidobacterium</i> и обогащение <i>Bacteroides Clostridiales</i> , в то время как микробное биоразнообразие в этой группе было обогащено / The colic group revealed a relative abundance of <i>Bifidobacterium</i> and an enrichment of <i>Bacteroides Clostridiales</i> , while microbial biodiversity was enriched in this group
Новикова В.П., 2023 [37] / Novikova V.P., 2023 [37]	Метод газовой хроматографии-масс-спектрометрии по Г.А. Осипову образцов кала / Method of gas chromatography-mass spectrometry of fecal samples according to G.A. Osipov	В группе колик значительно выше уровень <i>Acinetobacter</i> spp., <i>Nocardia</i> spp. и <i>Micromyctetes</i> spp. по сравнению со здоровыми / In the colic group, the level of <i>Acinetobacter</i> spp., <i>Nocardia</i> spp. and <i>Micromyctetes</i> spp. was significantly higher compared to healthy people

**Note:** SCFAs — short-chain fatty acids; PCR — polymerase chain reaction.

**Примечание:** КЦЖК — короткоцепочечные жирные кислоты; ПЦР — полимеразная цепная реакция.

crying duration in infants up to 3–4 months of age. These microorganisms include the family of gram-negative bacteria (Proteobacteria phylum), among which *Escherichia*, *Klebsiella*, and *Proteobacteria* species were predominant in stool samples of infants with colic [39, 42, 45]. Along with these microorganisms, *Serratia*, *Yersinia*, and *Vibrio* species were found in children with colic at the age of 2–4 weeks of life [42]. Two studies revealed significant differences in the content of *Acinetobacter* spp. [37, 42]. The first pathogenetic mechanism in IC connected with the increased content of Gram-negative opportunistic bacteria is excessive gas production as a result of fermentation of lactose, other carbohydrates and proteins. The second possible mechanism is an inflammatory response in the gut, which is triggered by the lipopolysaccharide complex of the outer envelope of Gram-negative bacteria resulting in increased production of pro-inflammatory cytokines and chemokines. High levels of fecal calprotectin and biomarkers of neutrophil infiltration in infants with colic evidence the above mentioned [22, 36]. Intestinal mucosa is more permeable due to inflammation which result in visceral hypersensitivity with clinical manifestation of IC symptoms. At the same time, *Bifidobacterium* and *Lactobacillus* microorganisms have an inverse association with colic symptoms in children during the first 3 months of life [34, 36, 45]. The pathogenetic mechanisms explaining the association of these microorganisms with the reduction of colic symptoms are the positive effects of *Lactobacilli* and lactic acid bacteria on the epithelial function of the intestinal mucosa, its barrier function and intestinal kinetics. Additionally, specific strains of *Bifidobacterium* and *Lactobacillus* have an anti-inflammatory response as they have antagonistic effects against gas-producing bacteria including *Escherichia*, *Klebsiella* and *Enterobacter* strains [46].

Each factor influencing on the formation of the intestinal microbiome (maternal microbiome and health status, mother's use of medications, type of delivery, condition of a child after birth, type of infant feeding, use of antibacterial drugs in a neonatal period) separately has no reliable significance in IC genesis [40, 47–49]. At the same time, it was proven that bacterial colonization was associated with malabsorption of fats and other nutrients due to immaturity of enterohepatic circulation of bile acids and salts [15, 24]. Microbiota produces local gut neurotransmit-

ters (serotonin, gamma-aminobutyric acid, melatonin, histamine, acetylcholine) and coordinates local adaptive responses to stressors through the system of neuroimmunoendocrine hierarchy. In addition, the microbiota can alter brain physiology through the production of a wide range of cytokines, short-chain fatty acids, and increased afferent nerve activity. This is the way the microbiota-brain axis works, and correspondingly plays a role in the genesis of IC [35].

Lactose tolerance disorder is a physiologic transient state in 3–4 months old infants, it often causes infantile colic. The literature describes the relationship between the severity of pain in infantile colic and the amount of carbohydrate excretion with feces in both breastfed and formula-fed infants. Data show that 25% of infants develop moderate to severe symptoms of colic dependent on cow's milk protein [50–53].

Mothers' conditions also contribute to predisposition of infantile colic, among them: unfavorable obstetric and gynecological history of the mother, gestosis, hypodynamia during pregnancy; nutritional disorders of the nursing mother (consumption of fatty foods, foods that increase flatulence, excessive amounts of cow's milk and its products); bad habits (smoking, alcohol, drugs); emotional stress in the family. Infants' contributions are prematurity; symptoms of post-hypoxic damage to the central nervous system; infant temperament. Incorrect feeding technique (swallowing air during feeding); force feeding; overfeeding; feeding from two breasts, improper preparation of nutritional formula (excessive or insufficient dilution), lack of proper mother-child interaction in the feeding situation also predispose to the development of infant colic [1].

The classic picture of colic is a dyad — extremely anxious parents and an infant with a persistent, piercing cry that is audiologically distinct from other infant cries [54]. Cry episodes are associated with hypertension, facial redness, pulling the legs up to an abdomen, and flatulence. Assessment of the infant during an episode of colic may indicate that the infant is in moderate to severe pain according to the FLACC scale (Face, Legs, Activity, Cry, Consolability scale, a measurement used to assess pain for children). [55]. The crying starts and stops abruptly on its own, i.e., the nature of the episodes is paroxysmal [55]. It is very difficult to calm the baby. Typical crying of a baby with colic is presented under the QR code.



XA circadian rhythm of crying (or "crying curve") with maximum intensity of crying and restlessness in the afternoon is specific for IC. An important characteristic of crying is its age-dependent appearance and dynamics: it appears from the 2nd week of life, peaks at 2–3 months of age with 6 then gradually decrease and disappears by 4–5 months of age.

The presence of multifactorial pathogenesis leads to difficulties in therapeutic approaches. There are no international consensus documents, and national guidelines compiled by experts from the standpoint of evidence-based medicine are available only in three countries: the UK, the USA, and Ireland [56, 57]. An analysis of the recommendations of these guidelines is presented in Table 2.

In Russia, infantile colic is described in the National Guidelines for Pediatric Gastroenterology [58] and in the 2022 recommendations of the Society of Pediatric Gastroenterologists, Hepatologists, and Nutritionists on Functional Gastrointestinal Tract Diseases [1, 59].

All domestic and foreign guidelines emphasize the need for an individualized approach to the treatment of IC in close cooperation with patient's parents. It is necessary to reassure parents about the transient and benign nature of infantile colic and favorable outcome, to inspire them with confidence in the absence of severe disease in the child. Changing family habits has positive effects, it might be proposed to create a regime of "feeding — activity — sleep"; maintain a positive relationship "child — mother / family". Timely detection of maternal depression, cruel attitude to the child, counseling parents about psychological problems will avoid unwarranted diagnostic intervention in children, as well as anxiety and insecurity in parents [1, 56–59].

Dietary correction measures are considered to be effective as well6 among them breastfeeding support, assessment of breastfeeding technique

and suckling efficiency. Most experts recommend preserving natural feeding [1, 56–59]. A. Cohen Engler (2012) indicated that exclusively breastfed infants had significantly lower rates of colic episodes and tended to have longer nighttime sleep in comparison with formula-fed infants [60]. The authors of the study measured melatonin levels in breast milk every 2 h during the day and found its significant increase during the night hours. It is now known that the circadian rhythm of melatonin in infants is established by 3–5 months of life, and regression of infantile colic is also noted around this age [30]. It was also found that infants with infantile colic had a statistically significant decrease in the level of melatonin in the blood in the morning hours and later establishment of the circadian rhythm of melatonin compared to the control group. It is possible that infantile colic may be associated with desynchronization of the normal circadian rhythm of melatonin, and breast milk, which contains the highest melatonin levels at night, may compensate a transient circadian rhythm deficiency in infants [23]. In addition, night breast milk probably exerts antispasmodic, antioxidant, anti-inflammatory, and immunoregulatory effects on intestinal wall permeability membrane and infant microbiome development [23, 28, 61].

Currently, there are no united nutritional recommendations for breastfeeding women. According to recommendations of the Rome IV criteria, elimination of cow's milk-based products from the diet of breastfeeding women is recognized as effective only in the presence of allergy to cow's milk protein [62]. In all other cases, a causal relationship between maternal diet and colic has not been proven. A number of studies recommend the use of a hypoallergenic diet (exclusion of cow's milk, eggs, peanuts and other nuts, wheat, soy and fish) and associate it with a reduction of colic symptoms in children [63]. A 2012 systematic review identified 1 randomized controlled trial in infants whose mothers followed a diet with low big eight allergens during one week. Questionnaires noted a reduction in crying by 60 minutes over 48 h, however, mothers did not report a subjective decrease of colic. In addition, only 60% of mothers in this study were able to fully comply with the elimination diet, emphasizing the difficulty in implementing dietary restrictions [29, 63]. Based on the above mentioned, most researchers believe that elimination diets are not recommended for breastfeeding mothers as a cure for infantile colic [1, 56–59].

**Table 2. Methods of treating colic from the point of view of evidence-based medicine****Таблица 2. Методы лечения колик с точки зрения доказательной медицины**

Рекомендация/предложение / Recommendation/proposal	UK, 2013, 2017 [56] / Великобритания, 2013, 2017 [56]	USA, 2015 [56] / США, 2015 [56]	Ireland, 2014 [57] / Ирландия, 2014 [57]
Клиническая оценка отношений матери и ребенка / Clinical assessment of the mother-child relationship	✓	✓	✓
Информация для родителей, советы, поддержка и уверенность / Parenting information, advice, support and reassurance	✓	✓	✓
Продолжение грудного вскармливания / Continued breastfeeding	✓	✓	
Модификация рациона матери / Modification of the mother's diet	✗	✓	
Смена смеси, если ребенок вскармливается смесью (+), если не выявлена аллергия на молоко) / Changing the formula if the baby is formula-fed (+ if an allergy to milk is not detected)	✗	✓	
Пробиотические добавки (++) младенцам, находящимся только на грудном вскармливании) / Probiotic supplements (++ breastfed-only infants)	✗	✓ +	✓
Симетикон / Simethicone	✗	✗	
Травяные добавки (например, фенхель) / Herbal supplements (such as fennel)	✗	✗	
Ингибиторы протонной помпы (например, омепразол, Лосек) / Proton pump inhibitors (eg, omeprazole, Losec)		✗	
Лактаза (например, капли Co-lief) / Lactase (eg Co-lief drops)	✗		
Антихолинергические препараты (включая дизикломин) / Anticholinergic drugs (including dicyclomine)		✗	
Детский массаж / Baby massage			✓
Мануальная терапия (включая манипуляции на позвоночнике и краинальную остеопатию) / Manual therapy (including spinal manipulation and cranial osteopathy)	✗	✗	
Физический контакт (например, удержание, раскачивание) / Physical contact (eg, holding, rocking)	✓		✓
«Белый шум» / «White noise»	✓		
Купание / Bathing	✓		
Обмотка (пеленание) / Winding	✓		
Пеленание / Swaddling		✗	
Акупунктура / Acupuncture		✗	
Режим сна / Sleeping mode			

**Note:** ✓ — recommended; ✓ + — high level of evidence; ✗ — not recommended; blank — not analyzed.

**Примечание:** ✓ — рекомендовано; ✓ + — высокий уровень доказательности, ✗ — не рекомендовано; пустая графа — не анализировалось.

According to systematic reviews, formula-fed infants of the first 3 months of life suffering from colic symptoms, are recommended to use partially hydrolyzed whey formulas with added prebiotics (oligosaccharides), formulas with reduced lactose content and fat component [1, 56–59].

Probiotic therapy has the highest level of evident efficacy among other therapeutic strategies in colic treatment [64–67]. Currently, the US Food and Drug Administration (FDA) has given probiotics a GRAS (Generally Recognized As Safe) status, which means: recognized as safe by leading FDA experts [48]. Taking into account the above mentioned pathogenetic mechanisms of the relationship between intestinal microflora and IC, the correction of intestinal microbiome seems promising in the point of reducing colic symptoms. The efficacy of different strains of *Lactobacillus reuteri* has been demonstrated in naturally fed infants [23, 24, 66–68]. The factors behind the effects of *L. reuteri* are studied well. These are the ability to form biofilms; the resistance of *L. reuteri* colonies to low pH and bile salts; the ability of *L. reuteri* attach to mucin, intestinal epithelium and intestinal epithelial cells; production of metabolites with antimicrobial and immunomodulatory effects, the most studied of which is reuterin, which inhibits a wide range of microorganisms, mainly Gram-negative bacteria, while the strains of *L. reuteri* show marked resistance to reuterin. Some strains of *L. reuteri*, in addition to reuterin, produce other antimicrobial substances: lactic acid, acetic acid, ethanol, reutericycline. Therefore *L. reuteri* is effective against various bacterial infections of the gastrointestinal tract: *Helicobacter pylori*, *E. coli*, *Clostridium difficile* and *salmonellae*. Moreover, *L. reuteri* produces metabolites with antiviral properties which are effective against pneumoviruses, circoviruses, rotaviruses, coxsackie viruses and papillomaviruses. In addition, there are reports that *L. reuteri* also stops the growth and kills various *Candida* species; some strains of *L. reuteri* inhibit the production of few pro-inflammatory cytokines, affect immune cells, produce folate and gamma-aminobutyric acid (GABA), which determine its effect on visceral sensitization [69].

It should be noted that the effects of different *L. reuteri* strains are strain specific. The proven effects of some *L. reuteri* strains are summarized in Table 3.

Placebo-controlled and comparative studies demonstrate different results of colic treatment

with *L. reuteri* probiotics, both positive and negative [75]. The data are summarized in Table 4.

In recent years, there has been increased interest in the use of other probiotic strains for the treatment of colic. The data are presented in Table 5.

Table 5 shows that *Lactobacillus rhamnosus* GG (ATCC 53103), *Bifidobacterium animalis* subsp. *lactis*, BB-12 and *B. breve* CECT7263 strains demonstrated a good therapeutic effect in colic in breastfed and formula-fed children. At the same time, multistain probiotics have been shown to have synergistic effects that individual strains cannot achieve independently. It is suggested that multistain probiotics may be effective in the treatment of colic due to their synergistic effects [88]. The data are summarized in Table 6.

Other pharmacologic agents that have been traditionally recommended for the relief of colic symptoms include simethicone, chamomile or fennel-based phytosupplements, other carminative and homeopathic preparations [4, 25, 92]. Most randomized clinical trials indicate low efficacy of these treatments. Concurrently, there is a lack of standardization of some homeopathic remedies consumption, as well as potential risks of undesirable effects. Thus, these remedies do not allow recommending most of them for the correction of infantile colic [21, 25, 56, 57, 93]. In some cases prescribed antispasmodics, proton pump inhibitors, and analgesics [3, 24, 66] have not proven effectiveness as well [56, 57]. Data published on lactase preparations for the treatment of colic is conflicting. There is evidence based on the results of randomized controlled trials (RCTs) showing a decrease in crying time in infants with proven lactose intolerance disorder when using lactase preparations compared to placebo [64]. At the same time, there are other RCTs indicating insufficient or weak effect of lactase preparations for relief of colic symptoms in infants on different types of feeding [65, 81]. It seems reasonable to recommend the use of lactase preparations only in case of proven lactase deficiency for 2 weeks. If there is no effect during this period of time, lactase therapy must be canceled.

It should be noted that a number of manipulations, such as infant massage, physical contact (e.g., holding, rocking an infant), bathing, swaddling and listening to the "white noise" have an evidence base for effectiveness against colic [56, 57]. The "white noise" is a background sound that contains frequencies of the entire sound range, from 20 to 20,000 Hz, it is similar with the sounds

**Table 3. Proven effects of different strains of *L. reuteri*****Таблица 3. Доказанные эффекты различных штаммов *L. reuteri***

Автор / Author	Штамм / Strain	Эффекты / Effects
Garcia Rode-nas C.L., 2016 [70]	<i>L. reuteri</i> DSM 17938	Снижение количества энтеробактерий и повышение числа бифидобактерий у детей, рожденных путем кесарева сечения, т.е. модулировало развитие кишечной микробиоты / A decrease in the number of enterobacteria and an increase in the number of bifidobacteria in children born by cesarean section, i.e. modulated the development of intestinal microbiota
Savino et al., 2015 [53]	<i>L. reuteri</i> DSM 17938	Снижение количества анаэробных грамотрицательных и увеличение количества грамположительных бактерий в кишечной микробиоте, тогда как содержание энтеробактерий и энтерококков в значительной степени снижено / A decrease in the number of anaerobic gram-negative and an increase in the number of gram-positive bacteria in the intestinal microbiota, while the content of enterobacteria and enterococci decreased significantly
Martoni C.J., 2015 [71]	<i>L. reuteri</i> NCIMB 30242	Увеличивает соотношение <i>Firmicutes</i> и <i>Bacteroidetes</i> / Increases the ratio of <i>Firmicutes</i> to <i>Bacteroidetes</i>
Savino F., 2009 [39]	<i>L. reuteri</i> DSM 17938	Увеличение количества лактобацилл и уменьшение <i>E. coli</i> в фекальной микробиоте / Increase in the number of lactobacilli and decrease in <i>E. coli</i> in the fecal microbiota
Savino et al., 2019 [72]	<i>L. reuteri</i> DSM 17938	Снижает восприятие боли двумя путями: через переходный рецепторный потенциал — ваниллоидный канал 1, влияя на калийзависимую активность кальциевых каналов и снижение вызванных капсаицином и растяжением потенциалов действия спинномозговых нервов / Reduces pain perception in two ways: through transient receptor potential — vanilloid channel 1, influencing potassium-dependent calcium channel activity and reducing capsaicin- and stretch-induced action potentials of spinal nerves
Hojšak I., 2019 [73]	<i>L. reuteri</i> DSM 17938	Снижение уровня фекального кальпротектина / Decrease in fecal calprotectin levels
Pour-mirzaiee M.A., 2020 [74]	<i>L. reuteri</i> LR92 (DSM 26866)	Выделяет уксусную кислоту, которая снижает pH <i>in vivo</i> и оказывает выраженное антибактериальное действие на многие патогены и реутерин, способный вызвать окислительный стресс у патогенов и эффективно предупреждать развитие воспалительной реакции / Produces acetic acid, which lowers pH <i>in vivo</i> and has a pronounced antibacterial effect on many pathogens and reuterin, which can cause oxidative stress in pathogens and effectively prevent the development of an inflammatory response
Новикова В.П., 2023 [37] / Novikova V.P., 2023 [37] /	<i>L. reuteri</i> DSM 17938	В группе детей, получавших <i>L. reuteri</i> , значительно снижался уровень <i>Bacillus megaterium</i> , <i>Bacteroides fragilis</i> и <i>Prevotella ruminicola</i> . Снижение уровня зонулина / In the group of children receiving <i>L. reuteri</i> , the level of <i>Bacillus megaterium</i> , <i>Bacteroides fragilis</i> and <i>Prevotella ruminicola</i> decreased significantly. Decreased zonulin levels

**Table 4. Results of placebo-controlled and comparative studies of treatment of colic with *L. reuteri* probiotics****Таблица 4. Результаты плацебоконтролируемых и сравнительных исследований лечения колик пробиотиками *L. reuteri***

Автор / Author	Штамм / Strain	Эффекты / Effects
<i>Лечение эффективно / Treatment is effective</i>		
Savino F., 2007 [76]	<i>L. reuteri</i> ATCC 55730	Снижение беспокойства и продолжительности крика / Reduced anxiety and cry duration
Szajewska H. et al., 2013 [77]	<i>L. reuteri</i> DSM 17938	Снижение беспокойства и продолжительности крика в сравнении с плацебо / Reduction in anxiety and cry duration compared to placebo

Ending of the table 4 / Окончание табл. 4

Автор / Author	Штамм / Strain	Эффекты / Effects
Chau K. et al., 2015 [78]	<i>L. reuteri</i> DSM 17938	Снижение беспокойства и продолжительности крика / Reduced anxiety and cry duration
Mi G.L. et al., 2015 [79]	<i>L. reuteri</i> DSM 17938	Снижение беспокойства и продолжительности крика / Reduced anxiety and cry duration
Tatari M. et al., 2017 [80]	<i>L. reuteri</i> DSM 17938	Снижение беспокойства и продолжительности крика / Reduced anxiety and cry duration
Dryl R., 2018 [81]	<i>L. reuteri</i> DSM 17938	Положительный лечебный и профилактический эффект исключительно у детей на грудном вскармливании (21–28 дней) / Positive therapeutic and preventive effect exclusively in breastfed children (21–28 days)
Novikova V.P., 2023 [37] / Новикова В.П., 2023 [37]	<i>L. reuteri</i> DSM 17938	Положительный лечебный и профилактический эффект в виде снижения плача менее 1 часа к 10-му дню лечения у детей, независимо от вида вскармливания / Positive therapeutic and preventive effect in the form of reduced crying for less than 1 hour by the 10th day of treatment in children, regardless of the type of feeding
<i>Лечение неэффективно / Treatment is ineffective</i>		
Sung V. et al., 2014 [82]	<i>L. reuteri</i> DSM 17938	Нет различий с группой плацебо / No difference with placebo group
Fatheree N.Y. et al., 2017 [83]	<i>L. reuteri</i> DSM 17938	При искусственном вскармливании не было получено положительного результата / No positive results were obtained with artificial feeding
Dryl R., 2018 [81]	<i>L. reuteri</i> DSM 17938	При искусственном вскармливании не было получено положительного результата / No positive results were obtained with artificial feeding

Table 5. Results of placebo-controlled studies of the treatment of colic with different single-strain probiotics

Таблица 5. Результаты плацебоконтролируемых исследований лечения колик разнымиmonoштаммовыми пробиотиками

Автор / Author	Штамм / Strain	Клинический эффект / Clinical effect	Патогенетический механизм / Pathogenetic mechanism
Savino F. et al., 2020 [45]	<i>Lactobacillus rhamnosus</i> GG (ATCC 53103)	Значительное снижение плача / Significant reduction in crying	Наблюдалось значительное увеличение общего количества бактерий в образцах кала ( <i>Lactobacillus</i> spp.) и значительное снижение уровня кальпротектина / There was a significant increase in total bacterial counts in stool samples ( <i>Lactobacillus</i> spp.) and a significant decrease in calprotectin levels
Xinias I. et al., 2017 [84]	<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> , BB-12	Значительное снижение времени плача, повышение качества жизни семьи / Significant reduction in crying time, improved family quality of life	Не изучался / Not studied
Nocerino R. et al., 2020 [85]	<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> , BB-12	Значительное снижение времени плача / Significant reduction in crying time	Достоверное увеличение HBD-2, LL-37, sIgA и бутират и снижение кальпротектина / Significant increase in HBD-2, LL-37, sIgA and butyrate and decrease in calprotectin

Ending of the table 5 / Окончание табл. 5

Автор / Author	Штамм / Strain	Клинический эффект / Clinical effect	Патогенетический механизм / Pathogenetic mechanism
Chen K. et al., 2021 [86]	<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> , BB-12	Значительное снижение времени плача / Significant reduction in crying time	Увеличение slgA, бутират в конце 21-дневного вмешательства, увеличение кальпротектина β-дефензина-2 и кателицидина / Increase in slgA, butyrate at the end of the 21-day intervention, increase in calprotectin β-defensin-2 and cathelicidin
Suanes-Cabello S., 2020 [87]	<i>B. breve CECT7263</i>	Большая эффективность в сокращении ежедневного времени плача у детей на грудном и искусственном вскармливании, чем в контроле / Greater effectiveness in reducing daily crying time in breastfed and bottle-fed children than in controls	Ингибирование роста <i>Enterobacteriaceae</i> spp., противовоспалительное действие / Inhibition of the growth of <i>Enterobacteriaceae</i> spp., anti-inflammatory effect

**Table 6. Results of placebo-controlled and comparative studies of the treatment of colic with different multi-strain probiotics****Таблица 6. Результаты плацебоконтролируемых и сравнительных исследований лечения колик разными мультиштаммовыми пробиотиками**

Авторы / Authors	Состав пробиотиков / Composition of probiotics	Клиническая эффективность / Clinical effectiveness
Gerasimov et al., 2018 [89]	<i>L. rhamnosus</i> 19070-2 + <i>L. reuteri</i> 12246 + фруктоолигосахарид и витамин D <sub>3</sub>	Значительная разница в среднем времени плача между пробиотиком и контрольной группой / Significant difference in mean crying time between probiotic and control group
Baldassarre et al., 2018 [90]	<i>L. paracasei</i> DSM 24733, <i>L. plantarum</i> DSM 24730, <i>L. acidophilus</i> DSM 24735 <i>L. delbrueckii</i> subsp. <i>bulgaricus</i> DSM 24734, <i>B. longum</i> DSM 24736, <i>B. breve</i> DSM 24732 <i>B. infantis</i> DSM 24737) <i>Streptococcus thermophilus</i> DSM 24731	Статистически значимое снижение количества минут плача в день. Незначительная разница в общем количестве пробиотических бактерий, лактобацилл и бифидобактерий была обнаружена между группами вмешательства и плацебо / A non-significant difference in the total counts of probiotic bacteria, lactobacilli and bifidobacteria was found between the intervention and placebo groups
Chen et al., 2021 [86]	<i>Bifidobacterium longum</i> CECT7894 + <i>Pediococcus pentosaceus</i> CECT8330	Значительное сокращение времени плача в группе вмешательства и улучшение консистенции стула / Significant reduction in crying time in the intervention group and improvement in stool consistency
Astó E. et al., 2022 [91]	<i>B. longum</i> KABP042 + <i>P. pentosaceus</i> KABP041	Уменьшение тяжести симптомов у младенцев, страдающих коликами и/или запором на грудном и искусственном вскармливании / Reducing the severity of symptoms in breastfed and formula-fed infants with colic and/or constipation
Novikova V. P. 2023 [37] / Новикова В.П., 2023 [37] /	<i>Lactobacillus casei</i> PXN 37, <i>Lactobacillus rhamnosus</i> PXN 54, <i>Streptococcus thermophilus</i> PXN 66, <i>Lactobacillus acidophilus</i> PXN 35, <i>Bifidobacterium breve</i> PXN 25, <i>Bifidobacterium infantis</i> PXN 27, <i>Bifidobacterium longum</i> PXN 30; и пребиотик: ФОС (фруктоолигосахариды)	Купирование колик к 6-му дню, что раньше, чем при использовании <i>L. reuteri</i> DSM 17938 (10-й день) и симптоматической терапии (12-й день). Увеличение уровня фекального зонулина на 44%, что больше, чем при использовании <i>L. reuteri</i> DSM 17938 (40%) и симптоматической терапии (10%). Увеличение количества таких доминирующих представителей микробиоты, как эубактерии и пропионобактерии / Relief of colic by day 6, which is earlier than when using <i>L. reuteri</i> DSM 17938 (day 10) and symptomatic therapy (day 12). Increase in fecal zonulin levels by 44%, which is greater than with the use of <i>L. reuteri</i> DSM 17938 (40%) and symptomatic therapy (10%). An increase in the number of such dominant representatives of the microbiota as eubacteria and propionobacteria




Fig. 1. Algorithm for diagnosing and treating colic (Vandenplas Y., 2016)

Рис. 1. Алгоритм диагностики и лечения колик (Vandenplas Y., 2016)

that the fetus hear in the womb hence it has a positive effect on the duration of crying and sleep in infants. However, there are limited studies that compare different treatments [37, 93].

Currently, the algorithm for diagnosis and treatment of colic proposed by ESPHAN (The European Society for Paediatric Gastroenterology Hepatology and Nutrition) experts in 2016 is generally accepted (Figure 1) [94].

Thus, infantile colic is a transient functional condition in children of the first 4–5 months of life that resolves on its own. However, it should always be remembered that serious pathologic conditions (gastrointestinal manifestations of food allergy, metabolic disorders, infectious processes, etc.) may hide under the mask of infantile colic, which requires differential diagnosis. Correction of IC symptoms is primarily based on psychological support of a family. With regard to breast-fed infants, breastfeeding support is man-

datory, as well as the use of probiotics with proven anti-colic properties (*Lactobacillus reuteri* DSM 17938). Mothers are recommended to correct diet if food intolerance is suspected. In case an infant under 3 months old suffers from infantile colic, when breastfeeding is not feasible, it is preferable to use partially hydrolyzed whey formula with reduced lactose content and enriched with prebiotics. Additional, well-organized studies comparing different therapeutic strategies for colic are needed to develop optimal therapeutic approaches.

## ADDITIONAL INFORMATION

**Author contribution.** Thereby, all authors made a substantial contribution to the conception of the study, acquisition, analysis, interpretation of data for the work, drafting and revising the article, final approval of the version to be published and agree to be accountable for all aspects of the study.

**Competing interests.** The authors declare that they have no competing interests.

**Funding source.** This study was not supported by any external sources of funding.

## ДОПОЛНИТЕЛЬНАЯ ИНФОРМАЦИЯ

**Вклад авторов.** Все авторы внесли существенный вклад в разработку концепции, проведение исследования и подготовку статьи, прочли и одобрили финальную версию перед публикацией.

**Конфликт интересов.** Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.

**Источник финансирования.** Авторы заявляют об отсутствии внешнего финансирования при проведении исследования.

## REFERENCES

- Havkin A.I., Fajzullina R.A., Bel'mer S.V. et al. Diagnostika i taktika vedeniya detey s funktsional'nymi zaporami. [Diagnostics and management of children with functional constipation]. Rekomendatsii obshchestva detskikh gastroenterologov. Voprosy detskoi dietologii. 2014; 12(4): 49–65. (in Russian).
- Wolke D., Bilgin A., Samara M. Systematic review and meta-analysis: fussing and crying durations and prevalence of colic in infants. J Pediatr. 2017; 185: 55–61. DOI: 10.1016/j.jpeds.2017.02.020.
- Heine R.G. Gastroesophageal reflux disease, colic and constipation in infants with food allergy. Curr Opin Allergy Clin Immunol. 2006; 6: 220–5. DOI: 10.1097/01.all.0000225164.06016.5d.
- Wessel M.A., Cobb J.C., Jackson E.B. et al. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics. 1954; 14: 421–35. PMID: 13214956.
- Benninga M.A., Faure C., Hyman P.E. et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2016; S0016-5085(16)00182-7–1455. DOI: 10.1053/j.gastro.2016.02.016.
- Morris S., James-Roberts I.S., Sleep J., Gillham P. Economic evaluation of strategies for managing infant crying and sleep problems. Arch Dis Child. 2001; 84(1): 15–9. PMCID: PMC1718606 DOI: 10.1136/adc.84.1.15.
- Halpern R., Coelho R. Excessive crying in infants. J Pediatr. 2016; 92: S40–5. DOI: 10.1016/j.jpeds.2016.01.004 11.
- Steutel N.F., Zeevenhooven J., Scarpato E. et al. Prevalence of functional gastrointestinal disorders in european infants and toddlers. J Pediatr. 2020; 221: 107–14. DOI: 10.1016/j.jpeds.2020.02.076.
- Gurova M.M. Mladencheskaya kolika s pozitsiy do-kazatel'noy meditsiny: rasprostranennost', printsipy differentsial'noy diagnostiki, algoritm vybora diyetoterapii. [Infantile colic from the perspective of evidence-based medicine: prevalence, principles of differential diagnosis and diet therapy algorithm]. Meditsinskiy Sovet. 2019; (17): 147–55. DOI: 10.21518/2079-701X-2019-17-147-155. (in Russian).
- Steutel N.F., Benninga M.A., Langendam M.W. et al. Developing a core outcome set for infant colic for primary, secondary and tertiary care settings: a prospective study. BMJ Open. 2017; 7: e015418. DOI: 10.1136/bmjopen-2016-015418.
- Johnson J.D., Cocker K., Chang E. Infantile colic: recognition and treatment. Am Fam Physician. 2015; 92: 577–82.
- Kurth E., Spichiger E., Cignacco E. et al. Predictors of crying problems in the early postpartum period. J Obstet Gynecol Neonatal Nurs. 2010; 39: 250–62. PMID: 20576068. DOI: 10.1111/j.1552-6909.2010.01141.x.
- Howard C.R., Lanphear N., Lanphear B.P. et al. Parental responses to infant crying and colic: the effect on breastfeeding duration. Breastfeed Med. 2006; 1: 146–55. DOI: 10.1089/bfm.2006.1.146.
- Overpeck M.D., Brenner R.A., Trumble A.C. et al. Risk factors for infant homicide in the United States. N Engl J Med. 1998; 339: 1211–6. DOI: 10.1056/NEJM199810223391706.
- Indrio F., Dargenio V.N., Francavilla R. et al. Infantile Colic and Long-Term Outcomes in Childhood: A Narrative Synthesis of the Evidence. Nutrients. 2023; 15(3): 615. DOI: 10.3390/nu15030615.
- Partty A., Kalliomaki M., Salminen S. Infant distress and development of functional gastrointestinal disorders in childhood: is there a connection? JAMA Pediatr. 2013; 167: 977–8.
- Savino F., Castagno E., Bretto R. et al. A prospective 10-year study on children who had severe infantile colic. Acta Paediatr Suppl. 2005; 94: 129–32.
- Romanello S., Spiri D., Marcuzzi E. et al. Association between childhood migraine and history of infantile colic. JAMA. 2013; 309: 1607–12.
- Barr R. The normal crying curve: what do we really know? Dev. Med. Child Neurol. 1990; 32(4): 356–62.
- Trevarthen C., Aitken K.J. Regression Periods in Human Infancy; ed. M. Heimann. Mahwah, NJ: Lawrence Erlbaum Associates; 2003: 107–84.
- Puchkova A.A., Degtyareva A.V., Zhdanova S.I., Golubtsova Yu.M. Mladencheskije koliki: sovremennyy vzglyad na patogeneticheskiye mekanizmy i lechebnyye meropriyatiya (obzor). [Infant colic: a new look at pathogenetic mechanisms and

- therapeutic measures (literature review)]. *Neonatology: News, Opinions, Training.* 2021; 9(1): 50–9. DOI: 10.33029/2308-2402-2021-9-1-50-59. (In Russian).
22. Novikova V.P., Bogdanova N.M., Magamedova D.M., Lapin S.V., Kuznecova D.A. K voprosu o patogeneze mladencheskih kolik/ V sbornike: Aktual'nye problemy abdominal'noj patologii u detej. Materialy Yubilejnogo XXX Kongressa detskih gastroenterologov Rossii i stran SNG. 2023. 31-33. (in Russian).
23. İnce T., Akman H., Çimrin D., Aydin A. The role of melatonin and cortisol circadian rhythms in the pathogenesis of infantile colic. *World J Pediatr.* 2018; 14(4): 392–8. DOI: 10.1007/s12519-018-0130-1.
24. Camilleri M., Park S.-Y., Scarpato E., Staiano A. Exploring hypotheses and rationale for causes of infantile colic. *Neurogastroenterol. Motil.* 2017; 29(2). Article ID 12943.
25. Anastasevich L.A. Kishechnyye koliki u detey rannego vozrasta: prichiny, diagnostika, lecheniye. [Intestinal colic in young children: causes, diagnosis, treatment]. *RMJ.* 2008; 3: 154–7. (in Russian).
26. Privorotsky V.F., Luppova N.E. Mladencheskiye kishechnyye koliki: problema i puti resheniya. [Infant intestinal colic: the problem and solutions]. *Pediatriya.* 2012; 91(4): 98–105. (in Russian).
27. Biagioli E., Tarasco V., Lingua C. et al. Pain-relieving agents for infantile colic. *Cochrane Database Syst. Rev.* 2016; 9(9). CD009999.
28. Katzer D., Pauli L., Mueller A. et al. Melatonin concentrations and antioxidative capacity of human breast milk according to gestational age and the time of day. *J. Hum. Lact.* 2016; 32(4): 105–10.
29. Kurtoglu S., Uzum K., Hallac I.K., Coskum A. 5-Hydroxy-3-indole acetic acid levels in infantile colic: is serotonergic tonus responsible for this problem? *Acta Paediatr.* 1997; 86(7): 764–5.
30. Anderson G., Vaillancourt C., Maes M., Reiter R.J. Breastfeeding and the gut-brain axis: is there a role for melatonin? *Biomol. Concepts.* 2017; 8(3-4): 185–95.
31. Bogdanova N.M., Belova E.M. The role of neuropeptides in the genesis of intestinal colic. [Rol' neuropeptidov v geneze kishechnykh kolik Farmateka]. *Pharmateca.* 2019; 26(2): 89–92. (in Russian).
32. Savino F., Grassino E.C., Guidi C. et al. Ghrelin and motilin concentration in colicky infants. *Acta Paediatr.* 2006; 95(6): 738–41.
33. de Weerth C., Fuentes S., Puylaert P., de Vos W.M. Intestinal microbiota of infants with colic: development and specific signatures. *Pediatrics.* 2013; 131(2): 550–8.
34. Pärty A., Kalliomäki M., Endo A., Salminen S., Isolauri E. Compositional development of Bifido-
- bacterium and *Lactobacillus* microbiota is linked with crying and fussing in early infancy. *PLoS One.* 2012; 7(3). Article ID 32495.
35. Shapovalova N.S., Novikova V.P. Os' kishechnik-mozg i yeye rol' v razvitiu funktsional'nykh gastrointestinal'nykh rasstroystv. [The gut-brain axis and its role in the development of functional gastrointestinal disorders]. *Children's Medicine of the North-West.* 2021; 9(4): 33–50. (in Russian).
36. Pärty A., Kalliomäki M., Salminen S., Isolauri E. Infantile colic is associated with low-grade systemic inflammation. *J. Pediatr. Gastroenterol. Nutr.* 2017; 64(5): 691–5.
37. Novikova V.P., Magomedova D.M., Blinov A.E. i dr. Mono- ili mul'tiprobiotiki? Sravnitel'noye klinicheskoye issledovaniye raznykh terapevticheskikh strategiy pri mladencheskih kolikakh. [Mono- or multiprobiotics? A comparative clinical study of different therapeutic strategies for infant colic]. *Medical advice.* 2023; 17 (17): 23-32. DOI: 10.21518/ms2023-313. (in Russian).
38. Savino F., Cresi F., Pautasso S. et al. Intestinal microflora in breastfed colicky and non-colicky infants. *Acta Paediatr.* 2004; 93: 825–9.
39. Savino F., Cordisco L., Tarasco V. et al. Molecular identification of coliform bacteria from colicky breastfed infants. *Acta Paediatr. Int J Paediatr.* 2009; 98(10): 1582–8. DOI: 10.1111/j.1651-2227.2009.01419.x.
40. Mentula S., Tuure T., Koskenala R. et al. Microbial composition and fecal fermentation end products from colicky infants — a probiotic supplementation pilot. *Microb Ecol Health Dis.* 2008; 20(1): 37–47.
41. de Weerth C., Fuentes S., Puylaert P., de Vos W.M. Intestinal microbiota of infants with colic: Development and specific signatures. *Pediatrics.* 2013; 131: e550–8. DOI: 10.1542/peds.2012-1449.
42. Rhoads J.M., Collins J., Fatheree N.Y. et al. Infant colic represents gut inflammation and dysbiosis. *J Pediatr.* 2018; 203: 55–61.e3. DOI: 10.1016/j.jpeds.2018.07.042.
43. Loughman A. et al. Infant microbiota in colic: Predictive associations with problem crying and subsequent child behavior. *J. Dev. Orig. Health Dis.* 2021; 12: 260–70. DOI: 10.1017/S2040174420000227.
44. Kozhakhetmetov S., Meirmanova Z., Mukhanbetzhanov N. et al. Compositional and functional variability of the gut microbiome in children with infantile colic. *Sci Rep.* 2023; 13(1): 9530. DOI: 10.1038/s41598-023-36641-z.
45. Savino F., Montanari P., Galliano I. et al. *Lactobacillus rhamnosus* GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial. *Nutrients.* 2020; 12(6): 1693. DOI: 10.3390/nu12061693.

46. Savino F., Cordisco L., Tarasco V. et al. Antagonistic effect of Lactobacillus strains against gas-producing coliforms isolated from colicky infants. *BMC Microbiol.* 2011; 30(11): 157.
47. Corvaglia L., Toni G., Martini S. et al. Influence of intrapartum antibiotic prophylaxis for group B Streptococcus on gut microbiota in the first month of life. *J. Pediatr. Gastroenterol. Nutr.* 2016; 62(2): 304–8.
48. Lucassen P.L., Assendelft W.J., van Eijk J.T. et al. Systematic review of the occurrence of infantile colic in the community. *Arch. Dis. Child.* 2001; 84(5): 398–403.
49. Rhoads J.M., Fatheree N.Y., Norori J. et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. *J. Pediatr.* 2009; 155(6): 823–8.e1.
50. Hofmann A.F. Enterohepatic Circulation of Bile Acids. *Comprehensive Physiology*. USA: John Wiley and Sons. 2011: 567–96.
51. Sarasu J.M., Narang M., Shah D. Infantile Colic: An Update. *Indian Pediatr.* 2018; 55(11): 979–87. Epub 2018 Jun 13. PMID: 29941700.
52. Titova O.N., Taran N.N. Kiskechnyye koliki u detey pervykh mesyatsev zhizni: kompleksnoye resheniye problemy. [Intestinal colic in children of the first months of life:a comprehensive solution to the problem]. *Pediatrics. Adj. to the journal. Consilium Medicum.* 2018; 1: 90–3. DOI: 10.26442/2413-8460\_2018.1.90-93. (in Russian).
53. Savino F., Zakharkova I.N., Borovik T.E. i dr. Novyye dannyye o lechenii kiskechnykh kolik u mладенцев. [New data on the treatment of intestinal colic in infants]. *Let's lie. pediatrics.* 2015; 14(5): 553–6. (in Russian).
54. Zeskind P.S., Barr R.G. Acoustic characteristics of naturally occurring cries of infants with "colic". *Child Dev.* 1997; 68: 394–403.
55. Merkel S.I., Voepel-Lewis T., Shayevitz J.R., Malviya S. The FLACC: A behavioral scale for scoring postoperative pain in young children. *Pediatr Nurs.* 1997; 23: 293–7.
56. UK NICE. Clinical Knowledge Summary Infant Colic 2017 and Postnatal care: routine postnatal care of women and their babies (NICE Guideline, 2015). Available at: <https://www.nice.org.uk>.
57. Ireland: Irish College of General Practitioners. Available at: <https://www.icgp.ie>.
58. Bel'mer S.V., Razumovskiy A.Yu., Khavkin A.I., red. Detskaya gastroenterologiya. [Pediatric gastroenterology]. Natsional'noye rukovodstvo. Moskva: GEOTAR-Media Publ.; 2022: 864.
59. Belmer S.V., Volynets G.V., Gorelov A.V. i dr. Funktsional'nyye rasstroystva organov pishchevareniya u detey. Rekomendatsii Obshchestva detskih gastroenterologov, hepatologov i nutritsiologov. Chast' 2. [Functional digestive disorders in children. Guidelines of the Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. Part 2]. *Russian Bulletin of Perinatology and Pediatrics.* 2020; 65(5): 100–11. DOI: 10.21508/1027-4065-2020-65-5-100-111. (In Russian).
60. Cohen Engler A., Hadash A., Shehadeh N., Pillar G. Breastfeeding may improve nocturnal sleep and reduce infantile colic: potential role of breast milk melatonin. *Eur. J. Pediatr.* 2012; 171(4): 729–32.
61. Dumbell R., Matveeva O., Oster H. Circadian clocks, stress, and immunity. *Front. Endocrinol. Lausanne.* 2016; 2(7): 37.
62. van Tilburg M.A.L., Hyman P.E., Walker L. et al. Prevalence of functional gastrointestinal disorders in infants and toddlers. *J Pediatr.* 2015; 166(3): 684–9. DOI: 10.1016/j.jpeds.2014.11.039.
63. Hill D.J., Roy N., Heine R.G. et al. Effect of a low-allergen maternal diet on colic among breastfed infants: a randomized, controlled trial. *Pediatrics.* 2005; 116(5): 709–15.
64. Gordon M., Biagioli E., Sorrenti M. et al. Dietary modifications for infantile colic. *Cochrane Database Syst. Rev.* 2018; 10(10). CD011029.
65. Harb T., Matsuyama M., David M., Hill R.J. Infant colic-what works: a systematic review of interventions for breast-fed infants. *J. Pediatr. Gastroenterol. Nutr.* 2016; 62(5): 668–86.
66. Hizli S., Can D., Kılıç I. et al. Diagnosis and Treatment Approaches in Infantile Colic (IC): Results of a Survey Among Paediatricians in Turkey. *Front Pediatr.* 2021; 9: 779997. DOI: 10.3389/fped.2021.779997.
67. Lacovou M., Ralston R.A., Muir J. et al. Dietary management of infantile colic: a systematic review. *Matern. Child Health J.* 2012; 16(6): 1319–31.
68. Hofmann A.F. Enterohepatic Circulation of Bile Acids. *Comprehensive Physiology*. USA: John Wiley and Sons. 2011: 567–96.
69. Novikova V.P., Magomedova D.M. Probioticheskiye svoystva shtammov lactobacillus reuteri (L. Reuteri). [Probiotic properties of lactobacillus reuteri (L. Reuteri) strains]. *Children's Medicine of the North-West.* 2023; 11(3): 36–5. DOI: 10.56871/CmN-W.2023.75.34.002. (in Russian).
70. Garcia Rodenas C.L., Lepage M., Ngom-Bru C. et al. Effect of Formula Containing Lactobacillus reuteri DSM 17938 on Fecal Microbiota of Infants Born by Cesarean-Section. *J Pediatr Gastroenterol Nutr.* 2016; 63(6): 681–7. DOI: 10.1097/MPG.0000000000001198.
71. Jones M.L., Martoni C.J., Prakash S. Oral supplementation with probiotic L. reuteri NCIMB 30242

- increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. *J Clin Endocrinol Metab.* 2013; 98(7): 2944–51. DOI: 10.1210/jc.2012-4262.
72. Savino F., Galliano I., Savino A. et al. Lactobacillus reuteri DSM 17938 Probiotics May Increase CC-Chemokine Receptor 7 Expression in Infants Treated With for Colic. *Front. Pediatr.* 2019; 7: 292. DOI: 10.3389/fped.2019.00292.
73. Hojsak I. Probiotics in functional gastrointestinal disorders. *Adv. Exp. Med. Biol.* 2019; 1125, 121–37. DOI: 10.1007/5584\_2018\_321.
74. Pourmirzaiee M.A., Famouri F., Moazeni W. et al. The efficacy of the prenatal administration of Lactobacillus reuteri LR92 DSM 26866 on the prevention of infantile colic: a randomized control trial. *Eur. J. Pediatr.* 2020; 179: 1619–26. DOI: 10.1007/s00431-020-03641-4.
75. Sheldon J.M., Alonso N. The Therapeutic Benefits of Single and Multi-Strain Probiotics on Mean Daily Crying Time and Key Inflammatory Markers in Infantile Colic. *Cureus.* 2022; 14(8): e28363. DOI: 10.7759/cureus.28363.
76. Savino F., Pelle E., Palumeri E. et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) simethicone in the treatment of infantile colic: a prospective randomized study. *Pediatrics.* 2007; 119: e124–30. DOI: 10.1542/peds.2006-1222.
77. Szajewska H., Dryl R. Probiotics for the Management of Infantile Colic. *J Pediatr Gastroenterol Nutr.* 2016; 63(Suppl 1): S22–4. DOI: 10.1097/MPG.0000000000001220.
78. Chau K., Lau E., Greenberg S. et al. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. *J Pediatr.* 2015; 166(1): 74–8. DOI: 10.1016/j.jpeds.2014.09.020.
79. Mi G.L., Zhao L., Qiao D.D. et al. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. *Antonie Van Leeuwenhoek.* 2015; 107(6): 1547–53. DOI: 10.1007/s10482-015-0448-9.
80. Tatari M., Yazdani Charati J., Karami H., Rouhanizadeh H. Effect of Probiotics on Infantile Colic Using the Quadratic Inference Functions. *Iranian Journal of Neonatology.* 2017; 8(3). DOI: 10.22038/ijn.2017.19901.1225.
81. Dryl R., Szajewska H. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. *Arch Med Sci.* 2018; 14(5): 1137–43. DOI: 10.5114/aoms.2017.66055.
82. Sung V., Hiscock H., Tang M.L. et al. Treating infant colic with the probiotic Lactobacillus reuteri: dou-
- ble blind, placebo controlled randomised trial. *BMJ.* 2014; 348: g2107.
83. Fathejee N.Y., Liu Y., Taylor C.M. et al. Lactobacillus reuteri for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *J Pediatr.* 2017; 191: 170–8.e2. DOI: 10.1016/j.jpeds.2017.07.036.
84. Xinias I., Analitis A., Mavroudi A. et al. Innovative Dietary Intervention Answers to Baby Colic. *Pediatr Gastroenterol Hepatol Nutr.* 2017; 20(2): 100–6. DOI: 10.5223/pghn.2017.20.2.100.
85. Nocerino R., De Filippis F., Cecere G. et al. The therapeutic efficacy of Bifidobacterium animalis subsp. lactis BB-12® in infant colic: A randomised, double blind, placebo-controlled trial. *Aliment Pharmacol Ther.* 2020; 51(1): 110–20. DOI: 10.1111/apt.15561.
86. Chen K., Zhang G., Xie H. et al. Efficacy of Bifidobacterium animalis subsp. lactis, BB-12® on infant colic — a randomised, double-blinded, placebo-controlled study. *Benef Microbes.* 2021; 12(6): 531–40. DOI: 10.3920/BM2020.0233.
87. Suanes-Cabello A. Efficacy of Bifidobacterium breve CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial. *Beneficial Microbes.* 2020; 1–14. DOI: 10.3920/bm2020.0105.
88. Kwoji I.D., Aiyegoro O.A., Okpeku M., Adeleke M.A. Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities. *Biology (Basel).* 2021; 10(4): 322. DOI: 10.3390/biology10040322.
89. Gerasimov S., Gantzel J., Dementieva N. et al. Role of Lactobacillus rhamnosus (FloraActive™) 19070-2 and Lactobacillus reuteri (FloraActive™) 12246 in infant colic: a randomized dietary study. *Nutrients.* 2018; 10(12): 1975. DOI: 10.3390/nu10121975.
90. Baldassarre M.E., Di Mauro A., Tafuri S. et al. Effectiveness and safety of a probiotic-mixture for the treatment of infantile colic: a double-blind, randomized, placebo-controlled clinical trial with fecal real-time PCR and NMR-based metabolomics analysis. *Nutrients.* 2018; 10(2): 195. DOI: 10.3390/nu10020195.
91. Astó E., Huedo P., Altadill T. et al. Probiotic Properties of Bifidobacterium longum KABP042 and *Pediococcus pentosaceus* KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol.* 2022; 12: 741391. DOI: 10.3389/fmicb.2021.741391.
92. Biagioli E., Tarasco V., Lingua C. et al. Pain-relieving agents for infantile colic. *Cochrane Database Syst. Rev.* 2016; 9(9). CD009999.
93. Ellwood J., Draper-Rodi J., Carnes D. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines. *BMJ Open.* 2020; 10(2). Article ID 035405.

94. Vandenplas Y., Benninga M., Broekaert I. et al. Functional gastro-intestinal disorder algorithms focus on early recognition, parental reassurance and nutritional strategies. *Acta Paediatr.* 2016; 105(3): 244–52. DOI: 10.1111/apa.13270.

## ЛИТЕРАТУРА

1. Хавкин А.И., Файзуллина Р.А., Бельмер С.В. и др. Диагностика и тактика ведения детей с функциональными запорами. Рекомендации общества детских гастроэнтерологов. Вопросы детской диетологии. 2014; 12(4): 49–65.
2. Wolke D., Bilgin A., Samara M. Systematic review and meta-analysis: fussing and crying durations and prevalence of colic in infants. *J Pediatr.* 2017; 185: 55–61. DOI: 10.1016/j.jpeds.2017.02.020.
3. Heine R.G. Gastroesophageal reflux disease, colic and constipation in infants with food allergy. *Curr Opin Allergy Clin Immunol.* 2006; 6: 220–5. DOI: 10.1097/01.all.0000225164.06016.5d.
4. Wessel M.A., Cobb J.C., Jackson E.B. et al. Paroxysmal fussing in infancy, sometimes called colic. *Pediatrics.* 1954; 14: 421–35. PMID: 13214956.
5. Benninga M.A., Faure C., Hyman P.E. et al. Childhood functional gastrointestinal disorders: neonate/toddler. *Gastroenterology.* 2016; S0016-5085(16)00182-7–1455. DOI: 10.1053/j.gastro.2016.02.016.
6. Morris S., James-Roberts I.S., Sleep J., Gillham P. Economic evaluation of strategies for managing infant crying and sleep problems. *Arch Dis Child.* 2001; 84(1): 15–9. PMCID: PMC1718606 DOI: 10.1136/adc.84.1.15.
7. Halpern R., Coelho R. Excessive crying in infants. *J Pediatr.* 2016; 92: S40–5. DOI: 10.1016/j.jpeds.2016.01.004 11.
8. Steutel N.F., Zeevenhooven J., Scarpato E. et al. Prevalence of functional gastrointestinal disorders in european infants and toddlers. *J Pediatr.* 2020; 221: 107–14. DOI: 10.1016/j.jpeds.2020.02.076.
9. Гурова М.М. Младенческая колика с позиций доказательной медицины: распространность, принципы дифференциальной диагностики, алгоритм выбора диетотерапии. Медицинский совет. 2019; (17): 147–55. DOI: 10.21518/2079-701X-2019-17-147-155.
10. Steutel N.F., Benninga M.A., Langendam M.W. et al. Developing a core outcome set for infant colic for primary, secondary and tertiary care settings: a prospective study. *BMJ Open.* 2017; 7: e015418. DOI: 10.1136/bmjopen-2016-015418.
11. Johnson J.D., Cocker K., Chang E. Infantile colic: recognition and treatment. *Am Fam Physician.* 2015; 92: 577–82.
12. Kurth E., Spichiger E., Cignacco E. et al. Predictors of crying problems in the early postpartum period. *J Obstet Gynecol Neonatal Nurs.* 2010; 39: 250–62. PMID: 20576068. DOI: 10.1111/j.1552-6909.2010.01141.x.
13. Howard C.R., Lanphear N., Lanphear B.P. et al. Parental responses to infant crying and colic: the effect on breastfeeding duration. *Breastfeed Med.* 2006; 1: 146–55. DOI: 10.1089/bfm.2006.1.146.
14. Overpeck M.D., Brenner R.A., Trumble A.C. et al. Risk factors for infant homicide in the United States. *N Engl J Med.* 1998; 339: 1211–6. DOI: 10.1056/NEJM199810223391706.
15. Indrio F., Dargenio V.N., Francavilla R. et al. Infantile Colic and Long-Term Outcomes in Childhood: A Narrative Synthesis of the Evidence. *Nutrients.* 2023; 15(3): 615. DOI: 10.3390/nu15030615.
16. Partty A., Kalliomaki M., Salminen S. Infant distress and development of functional gastrointestinal disorders in childhood: is there a connection? *JAMA Pediatr.* 2013; 167: 977–8.
17. Savino F., Castagno E., Bretto R. et al. A prospective 10-year study on children who had severe infantile colic. *ActaPaediatr Suppl.* 2005; 94: 129–32.
18. Romanello S., Spirì D., Marcuzzi E. et al. Association between childhood migraine and history of infantile colic. *JAMA.* 2013; 309: 1607–12.
19. Barr R. The normal crying curve: what do we really know? *Dev. Med. Child Neurol.* 1990; 32(4): 356–62.
20. Trevarthen C., Aitken K.J. Regression Periods in Human Infancy; ed. M. Heimann. Mahwah, NJ: Lawrence Erlbaum Associates; 2003: 107–84.
21. Пучкова А.А., Дегтярева А.В., Жданова С.И., Голубцова Ю.М. Младенческие колики: современный взгляд на патогенетические механизмы и лечебные мероприятия (обзор). Неонатология: новости, мнения, обучение. 2021; 9(1): 50–9. DOI: 10.33029/2308-2402-2021-9-1-50-59.
22. Новикова В.П., Богданова Н.М., Магамедова Д.М., Лапин С.В., Кузнецова Д.А. К вопросу о патогенезе младенческих колик/ В сборнике: Актуальные проблемы абдоминальной патологии у детей. Материалы Юбилейного XXX Конгресса детских гастроэнтерологов России и стран СНГ. 2023. 31–33.
23. İnce T., Akman H., Çimrin D., Aydin A. The role of melatonin and cortisol circadian rhythms in the pathogenesis of infantile colic. *World J Pediatr.* 2018; 14(4): 392–8. DOI: 10.1007/s12519-018-0130-1.
24. Camilleri M., Park S.-Y., Scarpato E., Staiano A. Exploring hypotheses and rationale for causes of infantile colic. *Neurogastroenterol. Motil.* 2017; 29(2). Article ID 12943.
25. Анастасевич Л.А. Кишечные колики у детей раннего возраста: причины, диагностика, лечение. *РМЖ.* 2008; 3: 154–7.

26. Приворотский В.Ф., Луппова Н.Е. Младенческие кишечные колики: проблема и пути решения. Педиатрия. 2012; 91(4): 98–105.
27. Biagioli E., Tarasco V., Lingua C. et al. Pain-relieving agents for infantile colic. Cochrane Database Syst. Rev. 2016; 9(9). CD009999.
28. Katzer D., Pauli L., Mueller A. et al. Melatonin concentrations and antioxidative capacity of human breast milk according to gestational age and the time of day. J. Hum. Lact. 2016; 32(4): 105–10.
29. Kurtoglu S., Uzüm K., Hallac I.K., Coskum A. 5-Hydroxy-3-indole acetic acid levels in infantile colic: is serotoninergic tonus responsible for this problem? Acta Paediatr. 1997; 86(7): 764–5.
30. Anderson G., Vaillancourt C., Maes M., Reiter R.J. Breastfeeding and the gut-brain axis: is there a role for melatonin? Biomol. Concepts. 2017; 8(3-4): 185–95.
31. Богданова Н.М., Белова Е.М. Роль нейропептидов в генезе кишечных колик. Фарматека. 2019; 26(2): 89–92.
32. Savino F., Grassino E.C., Guidi C. et al. Ghrelin and motilin concentration in colicky infants. Acta Paediatr. 2006; 95(6): 738–41.
33. de Weerth C., Fuentes S., Puylaert P., de Vos W.M. Intestinal microbiota of infants with colic: development and specific signatures. Pediatrics. 2013; 131(2): 550–8.
34. Pärty A., Kalliomäki M., Endo A., Salminen S., Isolauri E. Compositional development of Bifidobacterium and Lactobacillus microbiota is linked with crying and fussing in early infancy. PLoS One. 2012; 7(3). Article ID 32495.
35. Шаповалова Н.С., Новикова В.П. Ось кишечник-мозг и ее роль в развитии функциональных гастроинтестинальных расстройств. Children's Medicine of the North-West. 2021; 9(4): 33–50.
36. Pärty A., Kalliomäki M., Salminen S., Isolauri E. Infantile colic is associated with low-grade systemic inflammation. J. Pediatr. Gastroenterol. Nutr. 2017; 64(5): 691–5.
37. Новикова В.П., Магамедова Д.М., Блинов А.Е. и др. Моно- или мультипробиотики? Сравнительное клиническое исследование разных терапевтических стратегий при младенческих коликах. Медицинский совет. 2023; (17): 23–32. DOI: 10.21518/ms2023-313.
38. Savino F., Cresi F., Pautasso S. et al. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr. 2004; 93: 825–9.
39. Savino F., Cordisco L., Tarasco V. et al. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr. Int J Paediatr. 2009; 98(10): 1582–8. DOI: 10.1111/j.1651-2227.2009.01419.x.
40. Mentula S., Tuure T., Koskenala R. et al. Microbial composition and fecal fermentation end products from colicky infants — a probiotic supplementation pilot. Microb Ecol Health Dis. 2008; 20(1): 37–47.
41. de Weerth C., Fuentes S., Puylaert P., de Vos W.M. Intestinal microbiota of infants with colic: Development and specific signatures. Pediatrics. 2013; 131: e550–8. DOI: 10.1542/peds.2012-1449.
42. Rhoads J.M., Collins J., Fatheree N.Y. et al. Infant colic represents gut inflammation and dysbiosis. J Pediatr. 2018; 203: 55–61.e3. DOI: 10.1016/j.jpeds.2018.07.042.
43. Loughman A. et al. Infant microbiota in colic: Predictive associations with problem crying and subsequent child behavior. J. Dev. Orig. Health Dis. 2021; 12: 260–70. DOI: 10.1017/S2040174420000227.
44. Kozhakhmetov S., Meiirmanova Z., Mukhanbetzhanov N. et al. Compositional and functional variability of the gut microbiome in children with infantile colic. Sci Rep. 2023; 13(1): 9530. DOI: 10.1038/s41598-023-36641-z.
45. Savino F., Montanari P., Galliano I. et al. Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial. Nutrients. 2020; 12(6): 1693. DOI: 10.3390/nu12061693.
46. Savino F., Cordisco L., Tarasco V. et al. Antagonistic effect of Lactobacillus strains against gas-producing coliforms isolated from colicky infants. BMC Microbiol. 2011; 30(11): 157.
47. Corvaglia L., Tonti G., Martini S. et al. Influence of intrapartum antibiotic prophylaxis for group B Streptococcus on gut microbiota in the first month of life. J. Pediatr. Gastroenterol. Nutr. 2016; 62(2): 304–8.
48. Lucassen P.L., Assendelft W.J., van Eijk J.T. et al. Systematic review of the occurrence of infantile colic in the community. Arch. Dis. Child. 2001; 84(5): 398–403.
49. Rhoads J.M., Fatheree N.Y., Norori J. et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J. Pediatr. 2009; 155(6): 823–8.e1.
50. Hofmann A.F. Enterohepatic Circulation of Bile Acids. Comprehensive Physiology. USA: John Wiley and Sons. 2011: 567–96.
51. Sarasu J.M., Narang M., Shah D. Infantile Colic: An Update. Indian Pediatr. 2018; 55(11): 979–87. Epub 2018 Jun 13. PMID: 29941700.
52. Титова О.Н., Таран Н.Н. Кишечные колики у детей первых месяцев жизни: комплексное решение проблемы. Педиатрия. Прил. к журн. MConsilium Medicum. 2018; 1: 90–3. DOI: 10.26442/2413-8460\_2018.1.90-93.

53. Савино Ф., Захарова И.Н., Боровик Т.Э. и др. Новые данные о лечении кишечных колик у младенцев. Вопр. соврем. педиатрии. 2015; 14(5): 553–6.
54. Zeskind P.S., Barr R.G. Acoustic characteristics of naturally occurring cries of infants with "colic". Child Dev. 1997; 68: 394–403.
55. Merkel S.I., Voepel-Lewis T., Shayevitz J.R., Malviya S. The FLACC: A behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997; 23: 293–7.
56. UK NICE. Clinical Knowledge Summary Infant Colic 2017 and Postnatal care: routine postnatal care of women and their babies (NICE Guideline, 2015). Available at: <https://www.nice.org.uk>.
57. Ireland: Irish College of General Practitioners. Available at: <https://www.icgp.ie>.
58. Бельмер С.В., Разумовский А.Ю., Хавкин А.И., ред. Детская гастроэнтерология. Национальное руководство. М.: ГЭОТАР-Медиа; 2022.
59. Бельмер С.В., Волынец Г.В., Горелов А.В. и др. Функциональные расстройства органов пищеварения у детей. Рекомендации Общества детских гастроэнтерологов, гепатологов и нутрициологов. Часть 2. Российский вестник перинатологии и педиатрии. 2020; 65(5): 100–11. DOI: 10.21508/1027-4065-2020-65-5-100-111.
60. Cohen Engler A., Hadash A., Shehadeh N., Pillar G. Breastfeeding may improve nocturnal sleep and reduce infantile colic: potential role of breast milk melatonin. Eur. J. Pediatr. 2012; 171(4): 729–32.
61. Dumbell R., Matveeva O., Oster H. Circadian clocks, stress, and immunity. Front. Endocrinol. Lausanne. 2016; 2(7): 37.
62. van Tilburg M.A.L., Hyman P.E., Walker L. et al. Prevalence of functional gastrointestinal disorders in infants and toddlers. J Pediatr. 2015; 166(3): 684–9. DOI: 10.1016/j.jpeds.2014.11.039.
63. Hill D.J., Roy N., Heine R.G. et al. Effect of a low-allergen maternal diet on colic among breastfed infants: a randomized, controlled trial. Pediatrics. 2005; 116(5): 709–15.
64. Gordon M., Biagioli E., Sorrenti M. et al. Dietary modifications for infantile colic. Cochrane Database Syst. Rev. 2018; 10(10). CD011029.
65. Harb T., Matsuyama M., David M., Hill R.J. Infant colic—what works: a systematic review of interventions for breast-fed infants. J. Pediatr. Gastroenterol. Nutr. 2016; 62(5): 668–86.
66. Hizli S., Can D., Kılıç I. et al. Diagnosis and Treatment Approaches in Infantile Colic (IC): Results of a Survey Among Paediatricians in Turkey. Front Pediatr. 2021; 9: 779997. DOI: 10.3389/fped.2021.779997.
67. Lacovou M., Ralston R.A., Muir J. et al. Dietary management of infantile colic: a systematic review. Matern. Child Health J. 2012; 16(6): 1319–31.
68. Hofmann A.F. Enterohepatic Circulation of Bile Acids. Comprehensive Physiology. USA: John Wiley and Sons. 2011: 567–96.
69. Новикова В.П., Магамедова Д.М. Пробиотические свойства штаммов *Lactobacillus reuteri* (*L. reuteri*). Children's medicine of the North-West. 2023; 11(3): 36–5. DOI 10.56871/CmN-W.2023.75.34.002.
70. Garcia Rodenas C.L., Lepage M., Ngom-Bru C. et al. Effect of Formula Containing *Lactobacillus reuteri* DSM 17938 on Fecal Microbiota of Infants Born by Cesarean-Section. JPediatrGastroenterolNutr. 2016; 63(6): 681–7. DOI: 10.1097/MPG.0000000000001198.
71. Jones M.L., Martoni C.J., Prakash S. Oral supplementation with probiotic *L. reuteri* NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. J Clin Endocrinol Metab. 2013; 98(7): 2944–51. DOI: 10.1210/jc.2012-4262.
72. Savino F., Galliano I., Savino A. et al. *Lactobacillus reuteri* DSM 17938 Probiotics May Increase CC-Chemokine Receptor 7 Expression in Infants Treated With for Colic. Front. Pediatr. 2019; 7: 292. DOI: 10.3389/fped.2019.00292.
73. Hojsak I. Probiotics in functional gastrointestinal disorders. Adv. Exp. Med. Biol. 2019; 1125, 121–37. DOI: 10.1007/5584\_2018\_321.
74. Pourmirzaiee M.A., Famouri F., Moazeni W. et al. The efficacy of the prenatal administration of *Lactobacillus reuteri* LR92 DSM 26866 on the prevention of infantile colic: a randomized control trial. Eur. J. Pediatr. 2020; 179: 1619–26. DOI: 10.1007/s00431-020-03641-4.
75. Sheldon J.M., Alonso N. The Therapeutic Benefits of Single and Multi-Strain Probiotics on Mean Daily Crying Time and Key Inflammatory Markers in Infantile Colic. Cureus. 2022; 14(8): e28363. DOI: 10.7759/cureus.28363.
76. Savino F., Pelle E., Palumeri E. et al. *Lactobacillus reuteri* (American Type Culture Collection Strain 55730) simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007; 119: e124–30. DOI: 10.1542/peds.2006-1222.
77. Szajewska H., Dryl R. Probiotics for the Management of Infantile Colic. J. Pediatr. Gastroenterol. Nutr. 2016; 63(Suppl 1): S22–4. DOI: 10.1097/MPG.0000000000001220.
78. Chau K., Lau E., Greenberg S. et al. Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating *Lactobacillus reuteri* DSM 17938. J Pediatr. 2015; 166(1): 74–8. DOI: 10.1016/j.jpeds.2014.09.020.

79. Mi G.L., Zhao L., Qiao D.D. et al. Effectiveness of *Lactobacillus reuteri* in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. *Antonie Van Leeuwenhoek*. 2015; 107(6): 1547–53. DOI: 10.1007/s10482-015-0448-9.
80. Tatari M., Yazdani Charati J., Karami H., Rouhanizadeh H. Effect of Probiotics on Infantile Colic Using the Quadratic Inference Functions. *Iranian Journal of Neonatology*. 2017; 8(3). DOI: 10.22038/ijn.2017.19901.1225.
81. Dryl R., Szajewska H. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. *Arch Med Sci*. 2018; 14(5): 1137–43. DOI: 10.5114/aoms.2017.66055.
82. Sung V., Hiscock H., Tang M.L. et al. Treating infant colic with the probiotic *Lactobacillus reuteri*: double blind, placebo controlled randomised trial. *BMJ*. 2014; 348: g2107.
83. Fatheree N.Y., Liu Y., Taylor C.M. et al. *Lactobacillus reuteri* for Infants with Colic: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *J Pediatr*. 2017; 191: 170–8.e2. DOI: 10.1016/j.jpeds.2017.07.036.
84. Xinias I., Analitis A., Mavroudi A. et al. Innovative Dietary Intervention Answers to Baby Colic. *Pediatr Gastroenterol Hepatol Nutr*. 2017; 20(2): 100–6. DOI: 10.5223/pgahn.2017.20.2.100.
85. Nocerino R., De Filippis F., Cecere G. et al. The therapeutic efficacy of *Bifidobacterium animalis* subsp. *lactis* BB-12® in infant colic: A randomised, double blind, placebo-controlled trial. *Aliment Pharmacol Ther*. 2020; 51(1): 110–20. DOI: 10.1111/apt.15561.
86. Chen K., Zhang G., Xie H. et al. Efficacy of *Bifidobacterium animalis* subsp. *lactis*, BB-12® on infant colic — a randomised, double-blinded, placebo-controlled study. *Benef Microbes*. 2021; 12(6): 531–40. DOI: 10.3920/BM2020.0233.
87. Suanes-Cabello A. Efficacy of *Bifidobacterium breve* CECT7263 for infantile colic treatment: an open-label, parallel, randomised, controlled trial. *Beneficial Microbes*. 2020; 1–14. DOI: 10.3920/bm2020.0105.
88. Kwoji I.D., Aiyegoro O.A., Okpeku M., Adeleke M.A. Multi-Strain Probiotics: Synergy among Isolates Enhances Biological Activities. *Biology (Basel)*. 2021; 10(4): 322. DOI: 10.3390/biology10040322.
89. Gerasimov S., Gantzel J., Dementieva N. et al. Role of *Lactobacillus rhamnosus* (FloraActive™) 19070-2 and *Lactobacillus reuteri* (FloraActive™) 12246 in infant colic: a randomized dietary study. *Nutrients*. 2018; 10(12): 1975. DOI: 10.3390/nu10121975.
90. Baldassarre M.E., Di Mauro A., Tafuri S. et al. Effectiveness and safety of a probiotic-mixture for the treatment of infantile colic: a double-blind, randomized, placebo-controlled clinical trial with fecal real-time PCR and NMR-based metabolomics analysis. *Nutrients*. 2018; 10(2): 195. DOI: 10.3390/nu10020195.
91. Astó E., Huedo P., Altadill T. et al. Probiotic Properties of *Bifidobacterium longum* KABP042 and *Pediococcus pentosaceus* KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. *Front Microbiol*. 2022; 12: 741391. DOI: 10.3389/fmicb.2021.741391.
92. Biagioli E., Tarasco V., Lingua C. et al. Pain-relieving agents for infantile colic. *Cochrane Database Syst Rev*. 2016; 9(9). CD009999.
93. Ellwood J., Draper-Rodi J., Carnes D. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines. *BMJ Open*. 2020; 10(2). Article ID 035405.
94. Vandenplas Y., Benninga M., Broekaert I. et al. Functional gastro-intestinal disorder algorithms focus on early recognition, parental reassurance and nutritional strategies. *Acta Paediatr*. 2016; 105(3): 244–52. DOI: 10.1111/apa.13270.